164 related articles for article (PubMed ID: 31711137)
21. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
Padula WV; Ballreich J; Anderson GF
Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011
[TBL] [Abstract][Full Text] [Related]
22. A New Safe Harbor - Turning Drug Rebates into Discounts in Medicare Part D.
Gellad WF; Ennis M; Kuza CC
N Engl J Med; 2019 May; 380(18):1688-1690. PubMed ID: 30946552
[No Abstract] [Full Text] [Related]
23. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
24. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle.
Dusetzina SB; Bach PB
JAMA; 2019 Apr; 321(16):1563-1564. PubMed ID: 30840047
[No Abstract] [Full Text] [Related]
25. Encouraging generic use can yield significant savings.
Zimmerman C
Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
[TBL] [Abstract][Full Text] [Related]
26. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
27. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
28. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015.
Watanabe JH; Chau DL; Hirsch JD
J Am Geriatr Soc; 2018 Aug; 66(8):1621-1624. PubMed ID: 29972589
[TBL] [Abstract][Full Text] [Related]
29. Specialty Drugs - A Distinctly American Phenomenon.
Naci H; Kesselheim AS
N Engl J Med; 2020 Jun; 382(23):2179-2181. PubMed ID: 32492301
[No Abstract] [Full Text] [Related]
30. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
[No Abstract] [Full Text] [Related]
31. Pharmaceuticals and Medical Devices: Medicare Part D.
Steiner DJ;
Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116795
[No Abstract] [Full Text] [Related]
32. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
Bazalo G; Weiss RC
Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
[TBL] [Abstract][Full Text] [Related]
33. Beneficiary price sensitivity in the Medicare prescription drug plan market.
Frakt AB; Pizer SD
Health Econ; 2010 Jan; 19(1):88-100. PubMed ID: 19191252
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.
Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS
JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097
[TBL] [Abstract][Full Text] [Related]
36. Pharmaceuticals and medical devices: Medicare Part D.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403844
[No Abstract] [Full Text] [Related]
37. Rebates-The Little-Known Factor Behind Increasing Drug List Prices.
Rubin R
JAMA; 2020 Mar; 323(9):812-813. PubMed ID: 32125400
[No Abstract] [Full Text] [Related]
38. Providing prescription drug coverage to the elderly: America's experiment with Medicare Part D.
Duggan M; Healy P; Morton FS
J Econ Perspect; 2008; 22(4):69-92. PubMed ID: 19768843
[No Abstract] [Full Text] [Related]
39. Exploring the Valley of Savings: Minimizing Part D Costs and Optimizing Drug Therapy Outcomes in Medicare Beneficiaries With Developmental Disability.
Rogan EL; Ranson CA; Mori TK; Park SK; Lam HM; Legaspi JF; Tran LK; Cameros CJM; Blackburn AN; Lee ST; Valle-Oseguera CS; Pham CN; Woelfel JA; Patel RA
Intellect Dev Disabil; 2019 Jun; 57(3):234-241. PubMed ID: 31120407
[TBL] [Abstract][Full Text] [Related]
40. How insurers' bargaining power affects drug prices in Medicare Part D.
Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]